Yutaro Hino

Dr. Yutaro Hino

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2016 in Blood
Verified
Journal Article
Closed access
PDF file
KKKazuhiko Kakihana
Kazuhiko Kakihana
YFYuki Fujioka
Yuki Fujioka
WSWataru Suda
Wataru Suda
YNYuho Najima
Yuho Najima
GKGo Kuwata
Go Kuwata
KOKazuteru Ohashi
Kazuteru Ohashi
Increasing evidence indicates that the gut microbiota is closely associated with acute graft-versus-host disease (aGVHD) in stem cell transplantation (SCT). Fecal microbiota transplantation (FMT) could represent an alternative treatment option for aGVHD. However, FMT for SCT patients carries a potential risk of infection by infused microbiota because of the severely immunosuppressed status. We therefore conducted a pilot study to evaluate the safety of FMT in SCT. A total of 4 patients with steroid-resistant (n = 3) or steroid-dependent gut aGVHD (n = 1) received FMT. No severe adverse events attributed to FMT were observed. All patients responded to FMT, with 3 complete responses and 1 partial response. Temporal dynamics of microbiota seemed to be linked to the gut condition of patients and peripheral effector regulatory T cells also increased during response to FMT. FMT was safely performed in our patients and might offer a novel therapeutic option for aGVHD. This trial was registered at the University Hospital Medical Information Network (https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000017575) as #UMIN000015115. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points FMT was safely performed in SCT patients, with 3 complete responses and 1 partial response. Temporal microbiota dynamics seem linked to gut condition and effector regulatory T cells also increased during response to FMT.

23 April 2016 in SpringerPlus
Verified
Journal Article
Open access
PDF file
KHKaito Harada
Kaito Harada
SKShuhei Kurosawa
Shuhei Kurosawa
YHYutaro Hino
Yutaro Hino
KYKeita Yamamoto
Keita Yamamoto
MSMasahiro Sakaguchi
Masahiro Sakaguchi
KOKazuteru Ohashi
Kazuteru Ohashi
A high-flow nasal cannula (HFNC) is a newly developed device that enables high-flow oxygen therapy for patients with serious cardiopulmonary problems, but there are few data regarding its use in patients with hematological disease. The efficacy and tolerability of HFNCs for patients who developed ARF during the treatment of various hematological diseases was evaluated. Fifty-six patients underwent HFNC therapy during the last 2 years, and the causes of ARF were mainly pneumonia (n = 37) or acute congestive heart failure (n = 7). Only 11 patients (20 %) showed a good response to HFNC therapy, and remaining 45 patients (80 %) failed to respond to the initial HFNC therapy and, therefore, underwent second-line therapy including endotracheal intubation with mechanical ventilation (n = 15), non-invasive positive pressure ventilation (n = 1), or narcotic palliation alone (n = 29). Thus, HFNC appear not to be a viable treatment option in 4 out of 5 patients in this cohort of patients with hematological disease, but it was well tolerated in most patients (96 %); no major complications except for nasal soreness (n = 2) were observed. Multivariate analysis showed that the cause of ARF (pneumonia, odds ratio 11.2, 95 % CI 1.76–71.5, p = 0.01) was the only risk factor for treatment failure.

7 July 2015 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
SIShuntaro Ikegawa
Shuntaro Ikegawa
NDNoriko Doki
Noriko Doki
SKShuhei Kurosawa
Shuhei Kurosawa
TYTsukasa Yamaguchi
Tsukasa Yamaguchi
MSMasahiro Sakaguchi
Masahiro Sakaguchi
KOKazuteru Ohashi
Kazuteru Ohashi
Recent studies have shown that acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) exhibits a worse clinical outcome than AML not otherwise specified (AML-NOS). However, transplant outcomes of patients with AML-MRC have not been reported compared to patients with AML-NOS. We analyzed transplant outcomes among 147 patients with AML-MRC or AML-NOS who underwent allogeneic hematopoietic stem cell transplant (allo-HSCT) in a single institution. There were no significant differences in the 2-year overall survival (OS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM) between the two groups (2-year OS: 48% vs. 59%; 2-year CIR: 37% vs. 35%; 2-year NRM: 19% vs. 13%). Subgroup analysis adjusting for age and disease status demonstrated the same results between the two groups. Furthermore, multivariate analysis showed that AML-MRC was not an independent prognostic factor for poor prognosis in the setting of allo-HSCT (p = 0.7). These results suggest that allo-HSCT may overcome the poor prognosis of AML-MRC.

16 November 2015 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PDF file
SIShuntaro Ikegawa
Shuntaro Ikegawa
NDNoriko Doki
Noriko Doki
SKShuhei Kurosawa
Shuhei Kurosawa
TYTsukasa Yamaguchi
Tsukasa Yamaguchi
MSMasahiro Sakaguchi
Masahiro Sakaguchi
KOKazuteru Ohashi
Kazuteru Ohashi
Recent studies have shown that CD25 expression at the time of diagnosis of acute myeloid leukemia (AML) may be associated with an unfavorable outcome. We focus on AML patients without complete remission (CR) and examine the clinical correlation between surface CD25 expression at the time of transplantation and subsequent transplant outcomes.We observed a significant difference in overall survival (OS), disease-free survival (DFS) and cumulative incidence of relapse (CIR) between CD25 positive (+) and negative (−) groups (2-year OS; CD25 (+) group: 5% vs. CD25 (−) group: 40%, p < 0.0001, 2-year DFS; 5% vs. 29%, p < 0.0001, 2-year CIR; 77% vs. 52%, p = 0.03). Multivariate analysis showed that CD25 expression was an independent adverse factor for OS (p=0.002) and relapse (p=0.001).AML patients with residual CD25 positive blasts at the time of transplantation may require additional therapy before or after transplantation to improve survival.

21 December 2016 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
SIShuntaro Ikegawa
Shuntaro Ikegawa
NDNoriko Doki
Noriko Doki
SKSatoshi Kaito
Satoshi Kaito
SKShuhei Kurosawa
Shuhei Kurosawa
MSMasahiro Sakaguchi
Masahiro Sakaguchi
KOKazuteru Ohashi
Kazuteru Ohashi

10 November 2016 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
YHYutaro Hino
Yutaro Hino
NDNoriko Doki
Noriko Doki
YSYasushi Senoo
Yasushi Senoo
NSNoritaka Sekiya
Noritaka Sekiya
SKShuhei Kurosawa
Shuhei Kurosawa
KOKazuteru Ohashi
Kazuteru Ohashi